LY294002: Potent PI3K/Akt/mTOR Pathway Inhibitor for Cancer Research

Executive Summary: LY294002 is a cell-permeable, reversible inhibitor of class I PI3Ks with submicromolar potency against p110α, p110β, and p110δ catalytic subunits (IC₅₀: 0.5–0.97 μM) [ApexBio]. It inhibits PI3K signaling, leading to the suppression of Akt/mTOR activities, induction of apoptosis, and inhibition of autophagy [PNAS 2021]. LY294002 demonstrates stability and reversibility superior to wortmannin under standard laboratory conditions [ApexBio]. In vivo, it reduces tumor burden in OVCAR-3 xenograft models at 100 mg/kg daily dosing [ApexBio]. This article extends mechanistic insights, quantitative efficacy benchmarks, and operational guidance for optimal use in advanced cancer biology workflows.

Biological Rationale

The phosphoinositide 3-kinase (PI3K)/Akt/mTOR pathway is a central regulator of cell growth, proliferation, survival, and metabolism [PNAS 2021]. Aberrant activation of PI3K signaling is implicated in numerous cancers, including ovarian, breast, and prostate carcinomas. Class I PI3Ks, composed of catalytic subunits (p110α, p110β, p110δ), phosphorylate phosphatidylinositol-4,5-bisphosphate (PIP2) to generate PIP3, activating downstream signaling cascades. This pathway controls key cellular processes such as cell cycle progression, apoptosis resistance, and autophagy. Targeted inhibition of PI3K is a validated strategy to disrupt oncogenic signaling, induce apoptosis, and sensitize cancer cells to therapy. LY294002, a synthetic 2-(4-Morpholinyl)-8-phenyl-4H-l-benzopyran-4-one, was developed to selectively and reversibly inhibit class I PI3Ks, expanding the toolkit for mechanism-based cancer research [See also].

Mechanism of Action of LY294002

LY294002 competitively binds to the ATP-binding site of class I PI3K catalytic subunits p110α, p110β, and p110δ, inhibiting their kinase activity (IC₅₀: 0.5 μM, 0.97 μM, 0.57 μM, respectively) [ApexBio]. This blockade prevents the phosphorylation of PIP2 to PIP3, resulting in downstream inhibition of Akt (protein kinase B) and mammalian target of rapamycin (mTOR) signaling pathways. Inhibition of Akt/mTOR signaling suppresses cell growth, proliferation, and survival. LY294002 also inhibits autophagy by blocking autophagosome formation, as PIP3 is required for autophagic vesicle nucleation. At micromolar concentrations, LY294002 inhibits BET bromodomain proteins (BRD2, BRD3, BRD4), expanding its impact on transcriptional regulation. Unlike wortmannin, LY294002 is reversible and demonstrates improved chemical stability in DMSO and ethanol. Its effects are rapid, concentration-dependent, and reversible upon compound removal [PNAS 2021].

Evidence & Benchmarks

• LY294002 inhibits PI3K activity in vitro with IC₅₀ values of 0.5 μM (p110α), 0.97 μM (p110β), and 0.57 μM (p110δ) (ApexBio, https://www.apexbt.com/ly-294002.html).
• In OVCAR-3 ovarian carcinoma cells, LY294002 (1–10 μM) induces nuclear pyknosis and cytoplasmic shrinkage after 24 hours, consistent with apoptosis (ApexBio, https://www.apexbt.com/ly-294002.html).
• Daily intraperitoneal administration of LY294002 at 100 mg/kg for 3 weeks reduces tumor volume and cellularity in OVCAR-3 xenograft-bearing athymic nude mice (ApexBio, https://www.apexbt.com/ly-294002.html).
• LY294002 inhibits phosphorylation of downstream Akt and mTOR targets, suppressing cell proliferation and promoting apoptosis in cancer models (Kim et al., 2021, https://doi.org/10.1073/pnas.2103079118).
• BET bromodomain inhibition by LY294002 at micromolar concentrations disrupts BRD2/3/4-dependent transcriptional programs (ApexBio, https://www.apexbt.com/ly-294002.html).
• Compared to wortmannin, LY294002 demonstrates lower potency but superior stability and reversibility in standard laboratory solvents (ApexBio, https://www.apexbt.com/ly-294002.html).

Applications, Limits & Misconceptions

LY294002 is widely used to interrogate the PI3K/Akt/mTOR signaling axis in cancer, fibrosis, and autophagy research. Its reversible inhibition and operational stability make it a preferred tool for time-course and washout studies. The compound is also employed to modulate BET bromodomain activity in transcriptional regulation experiments. However, LY294002’s selectivity profile at higher concentrations may confound interpretation due to off-target effects. Its poor aqueous solubility requires careful stock preparation and solvent control. For diagnostic or clinical use, LY294002 is not approved and is strictly limited to research applications.

This article extends prior discussions by integrating recent mechanistic findings and practical workflow strategies. For a focus on cross-pathway signaling, see LY294002 in Cancer Biology: Beyond PI3K Inhibition, which highlights FGFR/TGFβ crosstalk. Our article clarifies the operational limits and expands quantitative benchmarks for translational models. For a practical troubleshooting guide, see LY294002: Potent PI3K Inhibitor for Advanced Cancer Biology; here, we provide updated evidence on in vivo efficacy and storage stability.

Common Pitfalls or Misconceptions

• Non-selectivity at high concentrations: At >10 μM, LY294002 may inhibit kinases beyond PI3Ks, impacting data interpretation.
• Solubility challenges: LY294002 is insoluble in water; improper stock preparation can lead to precipitation and inaccurate dosing.
• Not a clinical agent: LY294002 is for research use only, not for diagnostic or therapeutic applications.
• Irreversibility assumption: Effects are reversible; failure to perform washout may misattribute persistent pathway inhibition.
• BET bromodomain inhibition overlooked: At micromolar concentrations, LY294002 acts on BRD proteins, which should be controlled for in transcription-focused studies.

Workflow Integration & Parameters

Preparation: Dissolve LY294002 in DMSO (≥15.37 mg/mL) or ethanol (≥13.55 mg/mL) for stock solutions above 10 mM. Warm and sonicate to enhance solubility. Store stocks below -20°C and avoid repeated freeze-thaw cycles to prevent degradation [ApexBio].

In vitro: Use concentrations of 1–10 μM for cell-based assays. Monitor effects over 24–72 hours for apoptosis, proliferation, and autophagy endpoints.

In vivo: Typical dosing is 100 mg/kg intraperitoneally daily for 2–3 weeks in xenograft models. Monitor tumor volume and histological endpoints.

Controls: Include DMSO-only and untreated samples. For pathway specificity, consider using isoform-selective PI3K inhibitors or genetic knockdown.

Quality assurance: Confirm PI3K/Akt/mTOR pathway inhibition by immunoblotting for phospho-Akt and phospho-mTOR. Validate apoptosis induction with caspase activation or TUNEL staining. For autophagy, assess LC3-II accumulation and autophagosome formation.

For more on advanced workflow design, see Leveraging LY294002 for Next-Generation Cancer Biology, which provides actionable strategies for pathway interrogation. Our present article updates solubility and storage best practices based on recent product data.

Conclusion & Outlook

LY294002 remains a foundational tool for dissecting the PI3K/Akt/mTOR pathway and its downstream networks in cancer biology. Its balance of potency, reversibility, and operational stability enables precise experimental designs. Ongoing developments in isoform-selective PI3K inhibitors and combinatorial strategies may refine its use, but LY294002’s unique profile ensures its continued relevance for mechanistic and translational research. For ordering or detailed specifications, refer to the LY294002 A8250 product page.